All In Biotech

Drug Trial Radar · NCT06964230

A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects

A Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of T3D-959 in Subjects With Mild-to-Moderate Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: May 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 376 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

376

Planned (sponsor's estimate)

Start

Oct 26, 2026

Primary completion

Apr 2031

Study completion Jun 2031

Sponsor

Lead sponsor
T3D Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase 2b/3 clinical trial of a new candidate drug (T3D-959) to treat patients with mild-to-moderate Alzheimer's. The aims of the trial are to affirm potential therapeutic efficacy and safety observed in earlier clinical trials and assess the potential to modify the course of disease. The drug will be compared to placebo and administered orally to patients once a day for 78 weeks.

Conditions

  • Alzheimer's Disease

Interventions

  • T3D-959Drug

    Experimental: T3D-959 30 mg dose: T3D-959 is a small molecule dual nuclear receptor agonist that regulates transcription of genes, in particular those involved in glucose energy and lipid metabolism. T3D-959 is 15-times more potent for PPAR delta than for the secondary target of the drug, PPAR gamma. The 15 mg strength capsules contain 15mg T3D-959, pregelatinized starch NF, magnesium stearate NF, and size 0, hard gelatin, white/white, opaque, unmarked capsules. Subjects will ingest two size 0, 15mg capsules once per day in the morning.

  • Placebo ComparatorOther

    Placebo used to compare to T3D-959 drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline to end of treatment in ADAS-Cog13 and ADCS-iADLTime frame: 78 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • T3D Therapeutics, Inc.

    Durham, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.